Telix Pharmaceuticals Earnings & Forecasts

Telix Pharmaceuticals (TLX) earnings history, EPS estimates, revenue forecasts and company guidance.

Telix Pharmaceuticals Guidance

Telix Pharmaceuticals (TLX) last issued guidance on August 19, 2026 for fiscal year 2026. The company guided revenue in the range of for the period.

Compared to prior guidance, Telix Pharmaceuticals raised its revenue forecast from a prior range of $230M - $230M.

Telix Pharmaceuticals has issued 10 guidance updates between February 20, 2025 and July 21, 2026. During this period, the company raised its outlook 3 times and lowered it 4 times, providing investors with insight into management's evolving expectations.

Earnings & Guidance News

PRO
Reported Earlier, Telix Pharmaceuticals Guides FY 2026 Revenue Of $950M-$970M, Total Income Above $1B, Reaffirms R&D Guidance Of $230M-$270M

GuidanceFY 2026 revenue and other income are expected to be in excess of US$1 billion, with revenue progressing in line with the upper end of FY 2026 guidance of US$950 million to US$970 million and US$40 million of

Benzinga Newsdesk

Telix Pharmaceuticals Ltd